Novartis’s Inclisiran Unscathed As Arrowhead Falls Short
But NASH Candidate Generates Interest
Executive Summary
Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.
You may also be interested in...
$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.
COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.
CEOs Face Grilling On Vaccine Supply In EU
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports